Medications
Generic Ozempic Approved in Canada: What You Need to Know
GLP-1 Companion · 6 min read
Quick answer
Canada becomes the first G7 country to approve generic semaglutide. Health Canada has authorized the first generic version of Ozempic, potentially making GLP-1 medications more affordable for Canadians.
In a landmark decision on April 28, 2026, Health Canada approved the first generic version of semaglutide, making Canada the first G7 country to authorize a generic GLP-1 medication. This milestone could significantly impact affordability and access for Canadians who rely on Ozempic for diabetes management or weight loss treatment.
What Changed: Health Canada's Generic Approval
Health Canada assigned drug identification numbers to semaglutide injections manufactured by India-based Dr. Reddy's Laboratories Ltd. This approval marks a turning point in the availability of GLP-1 receptor agonists in Canada, following the expiration of Novo Nordisk's data exclusivity on January 4, 2026.
Canada became the first major Western market where generic semaglutide could be legally manufactured and sold after Novo Nordisk's patent protection ended earlier than expected due to a maintenance-fee issue with the patent office.
Expected Price Reductions
One of the most significant benefits of generic approval is the potential for substantial cost savings. According to the pan-Canadian Pharmaceutical Alliance pricing structure:
- First generic: 75-85% of brand-name Ozempic price
- Second generic enters market: 50% of brand-name price for both medications
- Three or more generics available: approximately 35% of brand-name Ozempic price
These projected price drops could make semaglutide significantly more accessible to Canadians who cannot afford the current brand-name costs.
More Generic Approvals Coming
The approval of Dr. Reddy's generic is just the beginning. Health Canada is currently reviewing eight additional applications for generic semaglutide from different companies. The regulatory agency expects to make more decisions in the coming weeks and months, which could lead to further price competition and increased availability.
What This Means for Canadian Patients
For Canadians with type 2 diabetes or those seeking GLP-1 treatment for weight management, generic semaglutide approval offers several advantages:
- Lower out-of-pocket costs for those without insurance coverage
- Potentially reduced prescription drug plan expenses
- Increased competition may drive innovation and improved formulations
- Better access for patients who previously couldn't afford Ozempic
Equivalency and Safety
Generic semaglutide approved by Health Canada meets the same rigorous quality, safety, and efficacy standards as brand-name Ozempic. The active ingredient is identical, though the inactive ingredients and delivery device may differ slightly. Patients can confidently switch between brand-name and generic versions under their doctor's guidance.
Timeline for Generic Availability
While Health Canada has approved the first generic, actual availability in Canadian pharmacies may take some time as manufacturers scale up production and work with distribution channels. Patients should speak with their pharmacists about when generic semaglutide will be available at their local pharmacy.
Global Impact
Canada's approval of generic semaglutide is significant not just nationally but globally. As the first G7 country to approve a generic GLP-1 medication, Canada sets a precedent that may influence regulatory decisions in other countries. This could accelerate the availability of affordable GLP-1 treatments worldwide.
Next Steps
If you're currently taking brand-name Ozempic or considering semaglutide treatment, speak with your healthcare provider about:
- Whether generic semaglutide would be appropriate for your situation
- When generic versions may become available through your pharmacy
- Potential cost savings with your insurance plan or as an uninsured patient
- Any differences between generic and brand-name formulations
The approval of generic semaglutide in Canada represents a major step forward in making effective GLP-1 medications more accessible and affordable for Canadians.